



## Nomination Committee for Acarix Annual General Meeting 2025

**A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been established for Acarix AB (publ) in accordance with the principles adopted by the annual general meeting held on May 14, 2024.**

Members of the Nomination Committee are:

- Jan Poulsen, representing Life Science Fund 1, MicroTech Software A/S and Jan Poulsen.
- Jacob Nossaman, representing RFR Holdings and JNOSS Holdings
- Philip Siberg, Chairman of the Board

The Nomination Committee is assigned to prepare proposals regarding Chairman of the Annual General Meeting, Board of Directors, Chairman of the Board of Directors, Auditor as well as Board remuneration and fee to the Auditor.

The Nomination Committee represents approximately 11 percent of the total voting rights of Acarix AB based on the ownership structure as of October 31, 2024.

Shareholders wishing to submit a proposal to the Nomination Committee may do so by sending an e-mail to: [valberedning@acarix.com](mailto:valberedning@acarix.com)

The Annual General Meeting (AGM) 2025 in Acarix will be held on May 15 of 2025, in Stockholm. Shareholders who wish to submit proposals for the AGM 2025 can send such requests in writing to Acarix AB (publ), c/o Regus Hyllie, Hyllie Boulevard 34, 5TR, SE- 215 32 Malmö, Sweden, or by e-mail to [agm@acarix.com](mailto:agm@acarix.com). Such requests must reach the company no later than April 15, 2025, to ensure that the company can include the request in the notice for the AGM.

### About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com)

11 November 2024 15:16:00 CET



**For more information, contact**

Ashley Wilson, phone +1405 413 5201, email [awilson@saxum.com](mailto:awilson@saxum.com)

**Attachments**

[Nomination Committee for Acarix Annual General Meeting 2025](#)